Published in Neuroimage on May 01, 2004
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Voxel-based assessment of gray and white matter volumes in Alzheimer's disease. Neurosci Lett (2009) 1.27
Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease. Stat Biopharm Res (2013) 1.03
A framework for detecting glaucomatous progression in the optic nerve head of an eye using proper orthogonal decomposition. IEEE Trans Inf Technol Biomed (2009) 0.95
Dopaminergic challenge with bromocriptine one month after mild traumatic brain injury: altered working memory and BOLD response. J Neuropsychiatry Clin Neurosci (2011) 0.94
Regional brain morphometry predicts memory rehabilitation outcome after traumatic brain injury. Front Hum Neurosci (2010) 0.92
Characterization of disease-related covariance topographies with SSMPCA toolbox: effects of spatial normalization and PET scanners. Hum Brain Mapp (2013) 0.92
Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response. Int J Psychophysiol (2011) 0.87
Magnetic resonance imaging of Alzheimer's disease. Eur Radiol (2006) 0.84
MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiol Aging (2015) 0.82
The functional connectivity landscape of the human brain. PLoS One (2014) 0.80
Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. Neuroepidemiology (2014) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain (2004) 7.38
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol (2006) 4.19
Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A (2002) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol (2003) 3.44
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol (2003) 3.26
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed (2009) 3.18
Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage (2002) 3.06
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage (2006) 2.94
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry (2010) 2.44
Posterior cortical atrophy. Lancet Neurol (2012) 2.41
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol (2010) 2.18
"-but who is that on the other side of you?" Extracampine hallucinations revisited. Lancet (2002) 2.16
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol (2010) 2.15
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol (2003) 2.07
Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol (2005) 2.06
Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain (2013) 2.05